(Q37690355)

English

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

scientific article published on 26 July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

0 references

0 references

0 references

author name string

Chamaida Plasencia

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dora Pascual-Salcedo

2

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Sara García-Carazo

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Leticia Lojo

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Laura Nuño

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Alejandro Villalba

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Diana Peiteado

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Florencia Arribas

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Jesus Díez

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Maria Teresa López-Casla

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Emilio Martín-Mola

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Alejandro Balsa

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

publication date

26 July 2013

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

R79

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Treatment recommendations for psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 August 2017

Spondyloarthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

6 September 2017

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

6 September 2017

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

23 June 2018

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3978754

1 September 2018

Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effect of drug interference in immunogenicity assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23890223

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37690355&oldid=2231830902"